33 results on '"Cortese, Riccardo"'
Search Results
2. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.
- Author
-
Cembrola, Biancamaria, Ruzza, Valentino, Troise, Fulvia, Esposito, Maria Luisa, Sasso, Emanuele, Cafaro, Valeria, Passariello, Margherita, Visconte, Feliciano, Raia, Maddalena, Del Vecchio, Luigi, D'Alise, Anna Morena, Cortese, Riccardo, Scarselli, Elisa, Zambrano, Nicola, De Lorenzo, Claudia, and Nicosia, Alfredo
- Subjects
- *
ANTIGEN analysis , *IMMUNOGLOBULIN analysis , *CELL proliferation , *ANTIGEN-antibody reactions , *FLOW cytometry , *GENE expression , *GENETIC engineering , *IMMUNOGLOBULINS , *LYMPHOCYTES , *MEDICAL protocols , *GENETIC mutation , *YEAST , *SEQUENCE analysis , *IN vitro studies - Abstract
The affinity engineering is a key step to increase the efficacy of therapeutic monoclonal antibodies and yeast surface display is the most widely used and powerful affinity maturation approach, achieving picomolar binding affinities. In this study, we provide an optimization of the yeast surface display methodology, applied to the generation of potentially therapeutic high affinity antibodies targeting the immune checkpoint PD-L1. In this approach, we coupled a 10-cycle error-prone mutagenesis of heavy chain complementarity determining region 3 of an anti‐PD-L1 scFv, previously identified by phage display, with high-throughput sequencing, to generate scFv-yeast libraries with high mutant frequency and diversity. In addition, we set up a novel, faster and effective selection scheme by fluorescence-activated cell sorting, based on a fast drop of the antigen concentration between the first and the last selection cycles, unlike the gradual decrease typical of current selection protocols. In this way we isolated 6 enriched mutated scFv-yeast clones overall, showing an affinity improvement for soluble PD-L1 protein compared to the parental scFv. As a proof of the potency of the novel approach, we confirmed that the antibodies converted from all the mutated scFvs retained the affinity improvement. Remarkably, the best PD-L1 binder among them also bound with a higher affinity to PD-L1 expressed in its native conformation on human-activated lymphocytes, and it was able to stimulate lymphocyte proliferation in vitro more efficiently than its parental antibody. This optimized technology, besides the identification of a new potential checkpoint inhibitor, provides a tool for the quick isolation of high affinity binders. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.
- Author
-
Spada, Enea, Rezza, Giovanni, Garbuglia, Anna Rosa, Lombardo, Flavia Lucia, Zuccaro, Ornella, Menniti Ippolito, Francesca, Cupellaro, Elisabetta, Capone, Stefania, Capobianchi, Maria Rosaria, Nicosia, Alfredo, Cortese, Riccardo, Folgori, Antonella, Mele, Alfonso, The Collaborative Study Group, and Collaborative Study Group
- Subjects
- *
HEPATITIS C virus , *DRUG abuse risk factors , *PROPORTIONAL hazards models , *SOCIODEMOGRAPHIC factors , *CONFIDENCE intervals , *PATIENTS - Abstract
So far, only three small outdated studies have investigated hepatitis C virus (HCV) incidence and risk factors among illicit drug users (DUs) in Italy. Thus, during 2007-2010, we conducted a prospective cohort study among DUs attending 17 Italian rehabilitation centers serving urban areas. Two hundred eighty-four HCV-uninfected DUs were prospectively followed by interview and anti-HCV antibody and RNA testing every 6 months. Incidence was calculated using the person-years method. Infection predictors were assessed by time-dependent Cox analysis. Participants were mostly male (83.4%), under opioid substitution therapy (OST) (78.9%), non-injecting DUs (67.9%), and with a mean age of 30.8. Ninety-one of 224 DUs initially under OST interrupted treatment during the follow-up. Overall HCV incidence was 5.83/100 person-years at risk (PYAR) [95% confidence intervals (CI), 3.63-9.38]. The incidence did not significantly differ according the participants' sociodemographic characteristics or the degree of urbanization of the towns involved in the study. The incidence was higher for DUs under than for those not under OST (6.23 vs 4.50/100 PYAR; p = 0.681). Incidence was also higher for those with than for those without OST interruption (7.17 vs 5.04/100 PYAR; p = 0.55). However, all these differences were non-significant. At last follow-up visit, a significant decrease in frequency of sharing equipment for preparation/using drugs (by injection or not) was observed by analyzing either the whole cohort or DUs under OST only. Anti-HCV seroconversion resulted independently associated with sharing drug preparation/use equipment, backloading, having a HCV-positive sexual partner, or household and (marginally) intravenous injection. In this study, HCV incidence was non-negligible and OST seemed to lack effectiveness in reducing it. In Italy, implementation of combined harm reduction interventions and antiviral treatment of chronically infected DUs would be needed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
- Author
-
Osman, Mohamed, Mistry, Anoop, Keding, Ada, Gabe, Rhian, Cook, Elizabeth, Forrester, Sarah, Wiggins, Rebecca, Di Marco, Stefania, Colloca, Stefano, Siani, Loredana, Cortese, Riccardo, Smith, Deborah F., Aebischer, Toni, Kaye, Paul M., and Lacey, Charles J.
- Subjects
- *
VISCERAL leishmaniasis , *LEISHMANIASIS , *T cells , *AMASTIGOTES , *VACCINATION , *DISEASE risk factors - Abstract
Background: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or appropriately targeted cell mediated immunity, including CD8+ T cell responses, underlies the progression of VL and progression to PKDL, and can limit the therapeutic efficacy of anti-leishmanial drugs. Hence, in addition to the need for prophylactic vaccines against leishmaniasis, the development of therapeutic vaccines for use alone or in combined immuno-chemotherapy has been identified as an unmet clinical need. Here, we report the first clinical trial of a third-generation leishmaniasis vaccine, developed intentionally to induce Leishmania-specific CD8+ T cells. Methods: We conducted a first-in-human dose escalation Phase I trial in 20 healthy volunteers to assess the safety, tolerability and immunogenicity of a prime-only adenoviral vaccine for human VL and PKDL. ChAd63-KH is a replication defective simian adenovirus expressing a novel synthetic gene (KH) encoding two Leishmania proteins KMP-11 and HASPB. Uniquely, the latter was engineered to reflect repeat domain polymorphisms and arrangements identified from clinical isolates. We monitored innate immune responses by whole blood RNA-Seq and antigen specific CD8+ T cell responses by IFNγ ELISPOT and intracellular flow cytometry. Findings: ChAd63-KH was safe at intramuscular doses of 1x1010 and 7.5x1010 vp. Whole blood transcriptomic profiling indicated that ChAd63-KH induced innate immune responses characterized by an interferon signature and the presence of activated dendritic cells. Broad and quantitatively robust CD8+ T cell responses were induced by vaccination in 100% (20/20) of vaccinated subjects. Conclusion: The results of this study support the further development of ChAd63-KH as a novel third generation vaccine for VL and PKDL. Trial registration: This clinical trial (LEISH1) was registered at EudraCT () and ISRCTN (). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.
- Author
-
Sasso, Emanuele, Paciello, Rolando, D’Auria, Francesco, Riccio, Gennaro, Froechlich, Guendalina, Cortese, Riccardo, Nicosia, Alfredo, De Lorenzo, Claudia, and Zambrano, Nicola
- Subjects
- *
HEPATITIS C diagnosis , *HEPATITIS C treatment , *CELL culture , *ENZYME-linked immunosorbent assay , *GENETIC techniques , *HEPATITIS C , *IMMUNOGLOBULINS , *MEMBRANE proteins , *MONOCLONAL antibodies , *PEPTIDES , *PHARMACEUTICAL technology , *POLYMERASE chain reaction , *RESEARCH funding , *DESCRIPTIVE statistics - Abstract
Expanding the availability of monoclonal antibodies interfering with hepatitis C virus infection of hepatocytes is an active field of investigation within medical biotechnologies, to prevent graft reinfection in patients subjected to liver transplantation and to overcome resistances elicited by novel antiviral drugs. In this paper, we describe a complete pipeline for screening of phage display libraries of human scFvs against native Claudin-1, a tight-junction protein involved in hepatitis C virus infection, expressed on the cell surface of human hepatocytes. To this aim, we implemented a high-throughput sequencing approach for library screening, followed by a simple and effective strategy to recover active binder clones from enriched sublibraries. The recovered clones were successfully converted to active immunoglobulins, thus demonstrating the effectiveness of the whole procedure. This novel approach can guarantee rapid and cheap isolation of antibodies for virtually any native antigen involved in human diseases, for therapeutic and/or diagnostic applications. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.
- Author
-
Quinn, Kylie M., Zak, Daniel E., Costa, Andreia, Ayako Yamamoto, Kastenmuller, Kathrin, Hill, Brenna J., Lynn, Geoffrey M., Darrah, Patricia A., Lindsay, Ross W. B., Lingshu Wang, Cheng Cheng, Nicosia, Alfredo, Folgori, Antonella, Colloca, Stefano, Cortese, Riccardo, Gostick, Emma, Price, David A., Gall, Jason G. D., Roederer, Mario, and Aderem, Alan
- Subjects
- *
ANTIGENS , *IMMUNITY , *IMMUNOGLOBULINS , *ADENOVIRUSES , *DNA viruses - Abstract
Recombinant adenoviral vectors (rAds) are lead vaccine candidates for protection against a variety of pathogens, including Ebola, HIV, tuberculosis, and malaria, due to their ability to potently induce T cell immunity in humans. However, the ability to induce protective cellular immunity varies among rAds. Here, we assessed the mechanisms that control the potency of CD8 Tcell responses in murine models following vaccination with human-, chimpanzee-, and simian-derived rAds encoding SIV-Gag antigen (Ag). After rAd vaccination, we quantified Ag expression and performed expression profiling of innate immune response genes in the draining lymph node. Human-derived rAd5 and chimpanzee-derived chAd3 were the most potent rAds and induced high and persistent Ag expression with low innate gene activation, while less potent rAds induced less Ag expression and robustly induced innate immunity genes that were primarily associated with IFN signaling. Abrogation of type I IFN or stimulator of IFN genes (STING) signaling increased Ag expression and accelerated CD8 T cell response kinetics but did not alter memory responses or protection. These findings reveal that the magnitude of rAd-induced memory CD8 T cell immune responses correlates with Ag expression but is independent of IFN and STING and provide criteria for optimizing protective CD8 T cell immunity with rAd vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation.
- Author
-
Lacek, Krzysztof, Urbanowicz, Richard A., Troise, Fulvia, De Lorenzo, Claudia, Severino, Valeria, Di Maro, Antimo, Tarr, Alexander W., Ferrara, Francesca, Ploss, Alexander, Temperton, Nigel, Ball, Jonathan K., Nicosia, Alfredo, Cortese, Riccardo, and Pessi, Antonello
- Subjects
- *
IMMUNOGLOBULINS , *PROTEIN analysis , *CHOLESTEROL , *ANTIVIRAL agents , *PEPTIDES - Abstract
The broadly neutralizing antibodies HIV 2F5 and 4E10, which bind to overlapping epitopes in the membrane-proximal external region of the fusion protein gp41, have been proposed to use a two-step mechanism for neutralization; first, they bind and preconcentrate at the viral membrane through their long, hydrophobic CDRH3 loops, and second, they form a high affinity complex with the protein epitope. Accordingly, mutagenesis of the CDRH3 can abolish their neutralizing activity, with no change in the affinity for the peptide epitope. We show here that we can mimic this mechanism by conjugating a cholesterol group outside of the paratope of an antibody. Cholesterol-conjugated antibodies bind to lipid raft domains on the membrane, and because of this enrichment, they show increased antiviral potency. In particular, we find that cholesterol conjugation (i) rescues the antiviral activity of CDRH3-mutated 2F5, (ii) increases the antiviral activity of WT 2F5, (iii) potentiates the non-membrane-binding HIV antibody D5 10-100-fold (depending on the virus strain), and (iv) increases synergy between 2F5 and D5. Conjugation can be made at several positions, including variable and constant domains. Cholesterol conjugation therefore appears to be a general strategy to boost the potency of antiviral antibodies, and, because membrane affinity is engineered outside of the antibody paratope, it can complement affinity maturation strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain.
- Author
-
Spencer, Alexandra J., Cottingham, Matthew G., Jenks, Jennifer A., Longley, Rhea J., Capone, Stefania, Colloca, Stefano, Folgori, Antonella, Cortese, Riccardo, Nicosia, Alfredo, Bregu, Migena, and Hill, Adrian V. S.
- Subjects
- *
MALARIA prevention , *T cells , *VIRAL vaccines , *VIRAL antigens , *VACCINATION , *MAJOR histocompatibility complex , *ADENOVIRUSES - Abstract
The orthodox role of the invariant chain (CD74; Ii) is in antigen presentation to CD4+ T cells, but enhanced CD8+ T cells responses have been reported after vaccination with vectored viral vaccines encoding a fusion of Ii to the antigen of interest. In this study we assessed whether fusion of the malarial antigen, ME-TRAP, to Ii could increase the vaccine-induced CD8+ T cell response. Following single or heterologous prime-boost vaccination of mice with a recombinant chimpanzee adenovirus vector, ChAd63, or recombinant modified vaccinia virus Ankara (MVA), higher frequencies of antigen-specific CD4+ and CD8+ T cells were observed, with the largest increases observed following a ChAd63-MVA heterologous prime-boost regimen. Studies in non-human primates confirmed the ability of Ii-fusion to augment the T cell response, where a 4-fold increase was maintained up to 11 weeks after the MVA boost. Of the numerous different approaches explored to increase vectored vaccine induced immunogenicity over the years, fusion to the invariant chain showed a consistent enhancement in CD8+ T cell responses across different animal species and may therefore find application in the development of vaccines against human malaria and other diseases where high levels of cell-mediated immunity are required. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses.
- Author
-
Chmielewska, Alicja M., Naddeo, Mariarosaria, Capone, Stefania, Ammendola, Virginia, Ke Hu, Meredith, Luke, Verhoye, Lieven, Rychlowska, Malgorzata, Rappuoli, Rino, Ulmer, Jeffrey B., Colloca, Stefano, Nicosia, Alfredo, Cortese, Riccardo, Leroux-Roels, Geert, Balfe, Peter, Bienkowska-Szewczyk, Krystyna, Meuleman, Philip, McKeating, Jane A., and Folgori, Antonella
- Subjects
- *
ADENOVIRUSES , *HEPATITIS C virus , *T cells , *IMMUNE response , *CHIMPANZEES - Abstract
Despite the recent progress in the development of new antiviral agents, hepatitis C virus (HCV) infection remains a major global health problem, and there is a need for a preventive vaccine. We previously reported that adenoviral vectors expressing HCV nonstructural proteins elicit protective T cell responses in chimpanzees and were immunogenic in healthy volunteers. Furthermore, recombinant HCV E1E2 protein formulated with adjuvant MF59 induced protective antibody responses in chimpanzees and was immunogenic in humans. To develop an HCV vaccine capable of inducing both T cell and antibody responses, we constructed adenoviral vectors expressing full-length and truncated E1E2 envelope glycoproteins from HCV genotype 1b. Heterologous prime-boost immunization regimens with adenovirus and recombinant E1E2 glycoprotein (genotype 1a) plus MF59 were evaluated in mice and guinea pigs. Adenovirus prime and protein boost induced broad HCV-specific CD8+ and CD4+ T cell responses and functional Th1-type IgG responses. Immune sera neutralized luciferase reporter pseudoparticles expressing HCV envelope glycoproteins (HCVpp) and a diverse panel of recombinant cell culture-derived HCV (HCVcc) strains and limited cellto- cell HCV transmission. This study demonstrated that combining adenovirus vector with protein antigen can induce strong antibody and T cell responses that surpass immune responses achieved by either vaccine alone. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Fusion of HCV Nonstructural Antigen to MHC Class II-associated Invariant Chain Enhances T-cell Responses Induced by Vectored Vaccines in Nonhuman Primates.
- Author
-
Capone, Stefania, Naddeo, Mariarosaria, D'Alise, Anna Morena, Abbate, Adele, Grazioli, Fabiana, Del Gaudio, Annunziata, Del Sorbo, Mariarosaria, Esposito, Maria Luisa, Ammendola, Virginia, Perretta, Gemma, Taglioni, Alessandra, Colloca, Stefano, Nicosia, Alfredo, Cortese, Riccardo, and Folgori, Antonella
- Subjects
- *
MAJOR histocompatibility complex , *T cells , *HEPATITIS viruses , *HLA histocompatibility antigens , *ANTINEOPLASTIC agents , *LYMPHOCYTES - Abstract
Despite viral vectors being potent inducers of antigen-specific T cells, strategies to further improve their immunogenicity are actively pursued. Of the numerous approaches investigated, fusion of the encoded antigen to major histocompatibility complex class II-associated invariant chain (Ii) has been reported to enhance CD8+ T-cell responses. We have previously shown that adenovirus vaccine encoding nonstructural (NS) hepatitis C virus (HCV) proteins induces potent T-cell responses in humans. However, even higher T-cell responses might be required to achieve efficacy against different HCV genotypes or therapeutic effect in chronically infected HCV patients. In this study, we assessed fusion of the HCV NS antigen to murine and human Ii expressed by the chimpanzee adenovirus vector ChAd3 or recombinant modified vaccinia Ankara in mice and nonhuman primates (NHPs). A dramatic increase was observed in outbred mice in which vaccination with ChAd3 expressing the fusion antigen resulted in a 10-fold increase in interferon-γ+ CD8+ T cells. In NHPs, CD8+ T-cell responses were enhanced and accelerated with vectors encoding the Ii-fused antigen. These data show for the first time that the enhancement induced by vector vaccines encoding li-fused antigen was not species specific and can be translated from mice to NHPs, opening the way for testing in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults.
- Author
-
Ogwang, Caroline, Afolabi, Muhammed, Kimani, Domtila, Jagne, Ya Jankey, Sheehy, Susanne H., Bliss, Carly M., Duncan, Christopher J. A., Collins, Katharine A., Garcia Knight, Miguel A., Kimani, Eva, Anagnostou, Nicholas A., Berrie, Eleanor, Moyle, Sarah, Gilbert, Sarah C., Spencer, Alexandra J., Soipei, Peninah, Mueller, Jenny, Okebe, Joseph, Colloca, Stefano, and Cortese, Riccardo
- Subjects
- *
PLASMODIUM falciparum , *MALARIA vaccines , *IMMUNOGENETICS , *IMMUNIZATION , *ADENOVIRUSES , *ANTIGENS , *CLINICAL trials - Abstract
Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI). Methodology: We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns. Results: ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC). Conclusions: ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted. Trial Registration: Pactr.org PACTR2010020001771828 Pactr.org PACTR201008000221638 ClinicalTrials.gov NCT01373879 NCT01373879 ClinicalTrials.gov NCT01379430 NCT01379430 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus.
- Author
-
Vitelli, Alessandra, Quirion, Mary R., Lo, Chia-Yun, Misplon, Julia A., Grabowska, Agnieszka K., Pierantoni, Angiolo, Ammendola, Virginia, Price, Graeme E., Soboleski, Mark R., Cortese, Riccardo, Colloca, Stefano, Nicosia, Alfredo, and Epstein, Suzanne L.
- Subjects
- *
INFLUENZA vaccines , *ANTIGENS , *LABORATORY mice , *ADENOVIRUSES , *BONOBO , *DISEASE vectors , *TRANSGENES , *NUCLEOPROTEINS , *DISEASES - Abstract
Among approximately 1000 adenoviruses from chimpanzees and bonobos studied recently, the Pan Adenovirus type 3 (PanAd3, isolated from a bonobo, Pan paniscus) has one of the best profiles for a vaccine vector, combining potent transgene immunogenicity with minimal pre-existing immunity in the human population. In this study, we inserted into a replication defective PanAd3 a transgene expressing a fusion protein of conserved influenza antigens nucleoprotein (NP) and matrix 1 (M1). We then studied antibody and T cell responses as well as protection from challenge infection in a mouse model. A single intranasal administration of PanAd3-NPM1 vaccine induced strong antibody and T cell responses, and protected against high dose lethal influenza virus challenge. Thus PanAd3 is a promising candidate vector for vaccines, including universal influenza vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Acti.
- Author
-
Pessi, Antonello, Langella, Annunziata, Capito`, Elena, Ghezzi, Silvia, Vicenzi, Elisa, Poli, Guido, Ketas, Thomas, Mathieu, Cyrille, Cortese, Riccardo, Horvat, Branka, Moscona, Anne, and Porotto, Matteo
- Subjects
- *
CELL membranes , *PEPTIDES , *DIMERIZATION , *NIPAH virus , *INFLUENZA viruses , *ANTIVIRAL agents - Abstract
Fusion between the viral and target cell membranes is an obligatory step for the infectivity of all enveloped virus, and blocking this process is a clinically validated therapeutic strategy. Viral fusion is driven by specialized proteins which, although specific to each virus, act through a common mechanism, the formation of a complex between two heptad repeat (HR) regions. The HR regions are initially separated in an intermediate termed 'prehairpin', which bridges the viral and cell membranes, and then fold onto each other to form a 6-helical bundle (6HB), driving the two membranes to fuse. HR-derived peptides can inhibit viral infectivity by binding to the prehairpin intermediate and preventing its transition to the 6HB. The antiviral activity of HR-derived peptides differs considerably among enveloped viruses. For weak inhibitors, potency can be increased by peptide engineering strategies, but sequence-specific optimization is time-consuming. In seeking ways to increase potency without changing the native sequence, we previously reported that attachment to the HR peptide of a cholesterol group ('cholesterol-tagging') dramatically increases its antiviral potency, and simultaneously increases its half-life in vivo. We show here that antiviral potency may be increased by combining cholesterol-tagging with dimerization of the HR-derived sequence, using as examples human para-influenza virus, Nipah virus, and HIV-1. Together, cholesterol-tagging and dimerization may represent strategies to boost HR peptide potency to levels that in some cases may be compatible with in vivo use, possibly contributing to emergency responses to outbreaks of existing or novel viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood- Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors.
- Author
-
Sheehy, Susanne H., Duncan, Christopher J. A., Elias, Sean C., Biswas, Sumi, Collins, Katharine A., O'Hara, Geraldine A., Halstead, Fenella D., Ewer, Katie J., Mahungu, Tabitha, Spencer, Alexandra J., Miura, Kazutoyo, Poulton, Ian D., Dicks, Matthew D. J., Edwards, Nick J., Berrie, Eleanor, Moyle, Sarah, Colloca, Stefano, Cortese, Riccardo, Gantlett, Katherine, and Long, Carole A.
- Subjects
- *
PLASMODIUM falciparum , *ANTIGENS , *MALARIA vaccines , *RECOMBINANT proteins , *IMMUNOGLOBULINS - Abstract
Background: Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection in a pre-specified primary endpoint of a Phase IIa/b clinical trial designed to assess vaccine efficacy. Cell-mediated responses, acting in conjunction with functional antibodies, may be necessary for immunity against blood-stage P. falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question. Methodology: We conducted a Phase Ia, non-randomized clinical trial in 16 healthy, malaria-naïve adults of the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines encoding two alleles (3D7 and FVO) of the P. falciparum blood-stage malaria antigen; apical membrane antigen 1 (AMA1). ChAd63- MVA AMA1 administered in a heterologous prime-boost regime was shown to be safe and immunogenic, inducing highlevel T cell responses to both alleles 3D7 (median 2036 SFU/million PBMC) and FVO (median 1539 SFU/million PBMC), with a mixed CD4+/CD8+ phenotype, as well as substantial AMA1-specific serum IgG responses (medians of 49 μg/mL and 41 μg/mL for 3D7 and FVO AMA1 respectively) that demonstrated growth inhibitory activity in vitro. Conclusions: ChAd63-MVA is a safe and highly immunogenic delivery platform for both alleles of the AMA1 antigen in humans which warrants further efficacy testing. ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be applied to numerous other diseases where strong cellular and humoral immune responses are required for protection. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors.
- Author
-
Sheehy, Susanne H, Duncan, Christopher JA, Elias, Sean C, Collins, Katharine A, Ewer, Katie J, Spencer, Alexandra J, Williams, Andrew R, Halstead, Fenella D, Moretz, Samuel E, Miura, Kazutoyo, Epp, Christian, Dicks, Matthew DJ, Poulton, Ian D, Lawrie, Alison M, Berrie, Eleanor, Moyle, Sarah, Long, Carole A, Colloca, Stefano, Cortese, Riccardo, and Gilbert, Sarah C
- Subjects
- *
CLINICAL trials , *PLASMODIUM falciparum , *ANTIGENS , *ADENOVIRUSES , *IMMUNOGLOBULIN G - Abstract
Efficacy trials of antibody-inducing protein-in-adjuvant vaccines targeting the blood-stage Plasmodium falciparum malaria parasite have so far shown disappointing results. The induction of cell-mediated responses in conjunction with antibody responses is thought to be one alternative strategy that could achieve protective efficacy in humans. Here, we prepared chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient vectors encoding the well-studied P. falciparum blood-stage malaria antigen merozoite surface protein 1 (MSP1). A phase Ia clinical trial was conducted in healthy adults of a ChAd63-MVA MSP1 heterologous prime-boost immunization regime. The vaccine was safe and generally well tolerated. Fewer systemic adverse events (AEs) were observed following ChAd63 MSP1 than MVA MSP1 administration. Exceptionally strong T-cell responses were induced, and these displayed a mixed of CD4+ and CD8+ phenotype. Substantial MSP1-specific serum immunoglobulin G (IgG) antibody responses were also induced, which were capable of recognizing native parasite antigen, but these did not reach titers sufficient to neutralize P. falciparum parasites in vitro. This viral vectored vaccine regime is thus a leading approach for the induction of strong cellular and humoral immunogenicity against difficult disease targets in humans. Further studies are required to assess whether this strategy can achieve protective efficacy against blood-stage malaria infection. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional ProfiIing.
- Author
-
Fogiietti, Cristiana, Filocamo, Gessica, Cundari, Enrico, De Rinaldis, Emanuele, Lahm, Armin, Cortese, Riccardo, and Steinkuhler, Christian
- Subjects
- *
HISTONE deacetylase , *DROSOPHILA , *RNA , *HISTONES , *GENE expression , *GENETIC regulation - Abstract
Zinc-dependent histone deacetylases (HDACs) are a family of hydrolases first identified as components of transcriptional repressor complexes, where they act by deacetylating lysine residues at the N-terminal extensions of core histones, thereby affecting transcription. To get more insight into the biological functions of the individual HDAC family members, we have used RNA interference in combination with microarray analysis in Drosophila S2 cells. Silencing of Drosophila HDAC1 (DHDAC1), but not of the other DHDAC family members, leads to increased histone acetylation. Silencing of either DHDAC1 or DHDAC3 leads to cell growth inhibition and deregulated transcription of both common and distinct groups of genes. Silencing DHDAC2 leads to increased tubulin acetylation levels but was not associated with a deregulation of gene expression. No growth of phenotype and no significant deregulation of gene expression was observed upon silencing of DHDAC4 and DHDACX. Loss of DHDAC1 or exposure of S2 cells to the small molecule HDAC inhibitor trichostatin both lead to a G2 arrest and were associated with significantly overlapping gene expression signatures in which genes involved in nucleobase and lipid metabolism, DNA replication, cell cycle regulation, and signal transduction were over-represented. A large number of these genes were shown to also be deregulated upon loss of the co-repressor SIN3 (Pile, L.A., Spellman, P. T., Katzenberger, R. J., and Wassarman, D. A. (2003) J. Biol. Chem. 278, 37840 -37848). We conclude the following. 1) DHDAC1 and -3 have distinct functions in the control of gene expression. 2) Under the tested conditions, DHDAC2, -4, and X have no detectable transcriptional functions in S2 cells. 3) The anti- proliferative and transcriptional effects of trichostatin are largely recapitulated by the loss of DHDAC1. 4) The deacetylase activity of DHDAC1 significantly contributes to the repressor function of SIN3. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
17. A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques.
- Author
-
Capone, Stefania, Meola, Annalisa, Ercole, Bruno Bruni, Vitelli, Alessandra, Pezzanera, Monica, Ruggeri, Lionello, Davies, Mary Ellen, Tafi, Rosalba, Santini, Claudia, Luzzago, Alessandra, Tong-Ming Fu, Bett, Andrew, Colloca, Stefano, Cortese, Riccardo, Nicosia, Aifredo, and Folgori, Antonella
- Subjects
- *
ADENOVIRUSES , *HEPATITIS C virus , *T cells , *IMMUNE response , *DNA viruses , *SUPPRESSOR cells , *IMMUNOSUPPRESSION , *CHIMPANZEES as laboratory animals - Abstract
Success in resolving hepatitis C virus (HCV) infection has been correlated to vigorous, multispecific, and sustained CD8+ T-cell response in humans and chimpanzees. The efficacy of inducing T-cell-mediated immunity by recombinant serotype 5 adenovirus vector has been proven in many animal models of infectious diseases, but its immunogenicity can be negatively influenced by preexisting immunity against the vector itself. To evaluate the less prevalent adenovirus serotype 6 (Ad6) as an alternative vector for and HCV vaccine development, we have generated serotype 5 and 6 adenoviral vectors directing expression of the nonstructural region of HCV (MRKAd5-NSmut and MRKAd6-NSmut). Immunogenicity studies in mice showed that the two vectors induced comparable T-cell responses but that only MRKAd6-NSmut was not suppressed in the presence of anti-Ad5 immunity. In contrast, preexisting anti-Ad5 immunity dramatically blunted the immunogenicity of the serotype 5-based HCV vector. Furthermore, MRKAd6-NSmut showed equivalent potency, breadth, and longevity of HCV-specific T-cell responses in rhesus macaques as the corresponding Ad5-based vector over a wide range of doses and was capable of boosting DNA-primed animals even if administered at low doses. These data support the use of the MRKAd6-NSmut for anti-HCV immunotherapy and, more generally, for the Ad6 serotype as a better genetic vaccine vehicle than Ad5. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
18. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
- Author
-
Folgori, Antonella, Capone, Stefania, Ruggeri, Lionello, Meola, Annalisa, Sporeno, Elisabetta, Ercole, Bruno Bruni, Pezzanera, Monica, Tafi, Rosalba, Arcuri, Mirko, Fattori, Elena, Lahm, Armin, Luzzago, Alessandra, Vitelli, Alessandra, Colloca, Stefano, Cortese, Riccardo, and Nicosia, Alfredo
- Subjects
- *
FLAVIVIRUSES , *HEPATITIS C virus , *LIVER diseases , *LIVER metastasis , *DNA vaccines , *IMMUNE system , *PREVENTIVE medicine - Abstract
Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus. Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8+ T lymphocytes that cross-reacted with vaccine and virus epitopes. These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
19. A Functionally Orthogonal Estrogen Receptor-Based Transcription Switch Specifically Induced by a Nonsteroid Synthetic Ligand
- Author
-
Gallinari, Paola, Lahm, Armin, Koch, Uwe, Paolini, Chantal, Nardi, Maria Chiara, Roscilli, Giuseppe, Kinzel, Olaf, Fattori, Daniela, Muraglia, Ester, Toniatti, Carlo, Cortese, Riccardo, De Francesco, Raffaele, and Ciliberto, Gennaro
- Subjects
- *
ESTROGEN , *ESTROGEN receptors , *SEX hormones , *GENE expression , *BIOCHEMISTRY - Abstract
Summary: It is highly desirable to design ligand-dependent transcription regulation systems based on transactivators unresponsive to endogenous ligands but induced by synthetic small molecules unable to activate endogenous receptors. Using molecular modeling and yeast selection, we identified an estrogen receptor ligand binding domain double mutant (L384M, M421G) with decreased affinity to estradiol and enhanced binding to compounds inactive on estrogen receptors. Nonresponsiveness to estrogen was achieved by additionally adding the G521R substitution while introducing an “antagonistic-type” side chain in the compound, as in 4-hydroxytamoxifen. The triple-substituted ligand binding domain is insensitive to physiological concentrations of estradiol and has nanomolar affinity for the ligand. In this binary system, both receptor and ligand are, therefore, reciprocally specific. The mutated variant in the context of a chimeric transcription factor provides tight, ligand-dependent regulation of reporter gene expression. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
20. Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor.
- Author
-
Bianchi, Elisabetta, Xiaoping Liang, Ingallinella, Paolo, Finotto, Marco, Chastain, Michael A., Jiang Fan, Tong-Ming Fu, Chang Song, Horton, Melanie S., Freed, Daniel C., Manger, Walter, Wen, Emily, Li Shi, Ionescu, Roxana, Price, Collen, Wenger, Marc, Emini, Emilio A., Cortese, Riccardo, Ciliberto, Gennaro, and Shiver, John W.
- Subjects
- *
INFLUENZA vaccines , *INFLUENZA , *VACCINES , *VIRUSES , *VIROLOGY - Abstract
Conventional influenza vaccines can prevent infection, but their efficacy depends on the degree of antigenic "match" between the strains used for vaccine preparation and those circulating in the population. A universal influenza vaccine based on invariant regions of the virus, able to provide broadly cross-reactive protection, without requiring continuous manufacturing update, would solve a major medical need. Since the temporal and geographical dominance of the influenza virus type and/or subtype (A/H3, A/H1, or B) cannot yet be predicted, a universal vaccine, like the vaccines currently in use, should include both type A and type B influenza virus components. However, while encouraging preclinical data are available for influenza A virus, no candidate universal vaccine is available for influenza B virus. We show here that a peptide conjugate vaccine, based on the highly conserved maturational cleavage site of the HA0 precursor of the influenza B virus hemagglutinin, can elicit a protective immune response against lethal challenge with viruses belonging to either one of the representative, non-antigenically cross-reactive influenza B virus lineages. We demonstrate that protection by the HA0 vaccine is mediated by antibodies, probably through effector mechanisms, and that a major part of the protective response targets the most conserved region of HA0, the P1 residue of the scissile bond and the fusion peptide domain. In addition, we present preliminary evidence that the approach can be extended to influenza A virus, although the equivalent HA0 conjugate is not as efficacious as for influenza B virus. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
21. Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro.
- Author
-
Migliaccio, Giovanni, Tomassini, Joanne E., Carroll, Steven S., Tomei, Licia, Altamura, Sergio, Bhat, Balkrishen, Bartholomew, Linda, Bosserman, Michele R., Ceccacci, Alessandra, Colwell, Lawrence F., Cortese, Riccardo, De Francesco, Raffaele, Eldrupt, Anne B., Getty, Krista L., Hou, Xiaoli S., LaFemina, Robert L., Ludmerer, Steven W., MacCoss, Malcolm, and McMasters, Daniel R.
- Subjects
- *
VIRAL replication , *HEPATITIS C virus , *GENETIC mutation , *BIOCHEMISTRY , *INTERFERONS - Abstract
The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate that 2'-C-methyl ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication. Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compounds in both replicon and isolated polymerase assays. Biochemical analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog. Importantly, the combination of these agents with interferon-α results in synergistic inhibition of HCV genome replication in cell culture. Furthermore, 2'-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses. These observations, together with the finding that 2'-C-methyl-guanosine in particular has a favorable pharmacological profile, suggest that this class of compounds may have broad utility in the treatment of HCV and other flavivirus infections. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
22. Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor.
- Author
-
Bartosch, Birke, Vitelli, Alessandra, Granier, Christelle, Goujon, Caroline, Dubuisson, Jean, Pascale, Simona, Scarselli, Elisa, Cortese, Riccardo, Nicosia, Alfredo, and Cosset, François-Loïc
- Subjects
- *
HEPATITIS C virus , *GLYCOPROTEINS , *CELL membranes - Abstract
Several cell surface molecules have been proposed as receptor candidates, mediating cell entry of hepatitis C virus (HCV) on the basis of their physical association with virions or with soluble HCV E2 glycoproteins. However, due to the lack of infectious HCV particles, evidence that these receptor candidates support infection was missing. Using our recently described infectious HCV pseudotype particles (HCVpp) that display functional E1E2 glycoprotein complexes, here we show that HCV is a pH-dependent virus, implying that its receptor component(s) mediate virion internalization by endocytosis. Expression of the CD81 tetraspanin in non-permissive CD81-negative hepato-carcinoma cells was sufficient to restore susceptibility to HCVpp infection, confirming its critical role as a cell attachment factor. As a cell surface molecule likely to mediate endosomal trafficking, we demonstrate that the human scavenger receptor class B type 1 (SR-B1), a high-density lipoprotein-internalization molecule that we previously proposed as a novel HCV receptor candidate due to its affinity with E2 glycoproteins, is required for infection of CD81-expressing hepatic cells. By receptor competition assays, we found that SR-B1 antibodies that blocked binding of soluble E2 could prevent HCVpp infectivity. Furthermore, we establish that the hyper-variable region 1 of the HCV E2 glycoprotein is a critical determinant mediating entry in SR-B1-positive cells. Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
23. Construction of an rtTA2s-m2/ttskid-Based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and Non-Human primates
- Author
-
Lamartina, Stefania, Silvi, Luisa, Roscilli, Giuseppe, Casimiro, Danilo, Simon, Adam J., Davies, Mary-Ellen, Shiver, John W., Rinaudo, Cira Daniela, Zampaglione, Immacolata, Fattori, Elena, Colloca, Stefano, Paz, Odalys Gonzalez, Laufer, Ralph, Bujard, Hermann, Cortese, Riccardo, Ciliberto, Gennaro, and Toniatti, Carlo
- Subjects
- *
TETRACYCLINE , *GENE therapy - Abstract
The tetracycline (Tc)-dependent system in its “on” version (rtTA system) displays a baseline activity in the uninduced state, severely limiting its potential applicability in human gene therapy. So far, two different strategies to circumvent this limitation have been described. On one side, co-expression of the tetracycline regulated repressor tTSkid has proved capable of substantially reducing the baseline activity of rtTA. On the other, novel versions of the activator, namely rtTA2s-S2 and rtTA2s-M2, with a lower basal activity have been engineered. We have combined these two approaches by co-expressing TSkid with the novel transactivators. Bicistronic vectors were constructed that co-express TSkid with rtTA, rtTA2s-S2, or rtTA2s M2, through an internal ribosome entry site (plasmids IRES-A, IRES-S2, and IRES-M2, respectively). IRES-M2 proved to be the most effective construct ex vivo: it displayed a negligible basal activity, > 1000 fold inducibility, and high responsiveness to doxycycline (Dox). Upon delivery as plasmid DNA in mouse muscles, IRES-M2 facilitated 1000-fold induction of serum alkaline phosphatase (SEAP) gene expression and long-term, stringent, and strictly Dox-dose-dependent regulation of erythropoietin (Epo) gene expression. Tight regulation of the gene encoding SEAP was demonstrated also in non-human primates. Notably, the system was induced in animals by Dox-dosing regimens comparable to those used in humans. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
24. Binding of the Hepatitis C Virus E3 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2.
- Author
-
Roccasecca, Rosa Maria, Ansuini, Helenia, Vitelli, Alessandra, Meola, Annalisa, Scarselli, Elisa, Acali, Stefano, Pezzanera, Monica, Ercole, Bruno Bruni, McKeating, Jane, Yagnik, Asutosh, Lahm, Armin, Tramontano, Anna, Cortese, Riccardo, and Nicosia, Alfredo
- Subjects
- *
GLYCOPROTEINS , *HYPERVARIABLE regions , *HEPATITIS C virus - Abstract
The envelope glycoprotein E2 of hepatitis C virus (HCV) is the target of neutralizing antibodies and is presently being evaluated as an HCV vaccine candidate. HCV binds to human cells through the interaction of E2 with the tetraspanin CD81, a putative viral receptor component. We have analyzed four different E2 proteins from la and lb viral isolates for their ability to bind to recombinant CD81 in vitro and to the native receptor displayed on the surface of Molt-4 cells. A substantial difference in binding efficiency between these E2 variants was observed, with proteins derived from lb subtypes showing significantly lower binding than the la protein. To elucidate the mechanism of E2-CD81 interaction and to identify critical regions responsible for the different binding efficiencies of the E2 variants, several mutants were generated in E2 protein regions predicted by computer modeling to be exposed on the protein surface. Functional analysis of these E2 derivatives revealed that at least two distinct domains are responsible for interaction with CD81. A first segment centered around amino acid residues 613 to 618 is essential for recognition, while a second element including the two hypervariable regions (HVRs) modulates E2 receptor binding. Binding inhibition experiments with anti-HVR monoclonal antibodies confirmed this mapping and supported the hypothesis that a complex interplay between the two HVRs of E2 is responsible for modulating receptor binding, possibly through intramolecular interactions. Finally, E2 proteins from different isolates displayed a profile of binding to human hepatic cells different from that observed on Molt-4 cells or isolated recombinant CD81, indicating that additional factors are involved in viral recognition by target liver cells. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
25. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.
- Author
-
Scarselli, Elisa, Ansuini, Helenia, Cerino, Raffaele, Roccasecca, Rosa Maria, Acali, Stefano, Filocamo, Gessica, Traboni, Cinzia, Nicosia, Alfredo, Cortese, Riccardo, and Vitelli, Alessandra
- Subjects
- *
HEPATITIS C virus , *HEPATOCELLULAR carcinoma , *LIVER cells , *CELL lines , *LIVER diseases , *CELL culture - Abstract
We discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81. Comparative binding studies using recombinant E2 from the most prevalent la and lb genotypes revealed that E2 recognition by hepatoma cells is independent from the viral isolate, while E2-CD81 interaction is isolate specific. Binding of soluble E2 to human hepatoma cells was impaired by deletion of the hypervariable region 1 (HYR1), but the wild-type phenotype was recovered by introducing a compensatory mutation reported previously to rescue infectivity of an HYR1-deleted HCV infectious clone. We have identified the receptor responsible for E2 binding to human hepatic cells as the human scavenger receptor class B type I (SR-BI). E2-SR-BI interaction is very selective since neither mouse SR-BI nor the closely related human scavenger receptor CD36, were able to bind E2. Finally, E2 recognition by SR-BI was competed out in an isolate-specific manner both on the hepatoma cell line and on the human SR-BI-transfected cell line by an anti-HYR1 monoclonal antibody. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
26. The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA.
- Author
-
Vannini, Alessandro, Volpari, Cinzia, Gargioli, Cesare, Muraglia, Ester, Cortese, Riccardo, De Francesco, Raffaele, Neddermann, Petra, and Di Marco, Stefania
- Subjects
- *
AGROBACTERIUM tumefaciens , *PLANT diseases , *TUMORS , *DNA , *GENE expression , *ADENOSINE triphosphatase gene expression , *GENETIC regulation - Abstract
The quorum sensing system allows bacteria to sense their cell density and initiate an altered pattern of gene expression after a sufficient quorum of cells has accumulated. In Agrobacterium tumefaciens, quorum sensing controls conjugal transfer of the tumour-inducing plasmid, responsible for plant crown gall disease. The core components of this system are the transcriptional regulator TraR and its inducing ligand N-(3-oxo-octanoyl)-L-homoserine lactone. This complex binds DNA and activates gene expression. We have determined the crystal structure of TraR in complex with its autoinducer and target DNA (PDB code 1h0m). The protein is dimeric, with each monomer composed of an N-terminal domain, which binds the ligand in an enclosed cavity far from the dimerization region, and a C-terminal domain, which binds DNA via a helix-turn-helix motif. The structure reveals an asymmetric homodimer, with one monomer longer than the other. The N-terminal domain resembles GAF/PAS domains, normally fused to catalytic signalling domains. In TraR, the gene fusion is between a GAF/PAS domain and a DNA-binding domain, resulting in a specific transcriptional regulator involved in quorum sensing. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
27. ADAM-HCV, a new-concept diagnostic assay for antibodies to hepatitis C virus in serum.
- Author
-
Minenkova, Olga, Gargano, Nicola, De Tomassi, Amedeo, Bellintani, Francesca, Pucci, Andrea, Fortugno, Paola, Fuscaldi, Elena, Pessi, Antonello, Rapicetta, Maria, Miceli, Michela, Iudicone, Paola, Cortese, Riccardo, Felici, Franco, and Monaci, Paolo
- Subjects
- *
BIOLOGICAL assay , *HEPATITIS C virus - Abstract
We screened phage libraries using sera from noninfected individuals and patients infected by hepatitis C virus (HCV). By applying different selection and maturation strategies, we identified a wide collection of efficient phage-borne ligands for HCV-specific antibodies. The selected ligands retained their antigenic properties when expressed as multimeric synthetic peptides. Peptides that mimic several immunodominant epitopes of the virus were used to develop a novel type of diagnostic assay which efficiently detects antibodies to HCV in serum. This type of analysis provides a conclusive diagnosis for many patients identified as indeterminate according to presently available serological assays. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
28. DNA-based selection and screening of peptide ligands.
- Author
-
Bartoli, Fabrizia, Nuzzo, Maurizio, Urbanelli, Lorena, Bellintani, Francesca, Prezzi, Caterina, Cortese, Riccardo, and Monaci, Paolo
- Subjects
- *
PEPTIDES , *LIGANDS (Biochemistry) , *HEPATITIS C virus - Abstract
Phage display selection strategies rely on the physical link between the displayed heterologous protein ligand and the DNA encoding it. Thus, genes expressing a ligand with a specific binding affinity can be selected rapidly. To improve the specificity and sensitivity of this technology for potential use in identifying ligands to a specific antibody present in a complex mixture, we incorporated a DNA selection step along with the phage display technology. Ligands for hepatitis C virus (HCV) antibodies present in serum were identified by panning a phage-displayed random peptide library against pools of serum HCV antibodies. An additional DNA hybridization screening step using single-stranded DNA isolated from one of the pools increased the specificity and sensitivity, resulting in the selection of an HCV antibody ligand with diagnostic potential. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
29. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants.
- Author
-
Puntoriero, Giulia, Meola, Annalisa, Lahm, Armin, Zucchelli, Silvia, Ercole, Bruno Bruni, Tafi, Rosalba, Pezzanera, Monica, Mondelli, Mario U., Cortese, Riccardo, Tramontano, Anna, Galfre, Giovanni, and Nicosia, Alfredo
- Subjects
- *
PROTEINS , *HEPATITIS C virus , *ANTIGENS , *VIRAL genomes , *HETEROGENEITY , *VIRUS diseases , *IMMUNE response , *IMMUNOGLOBULINS - Abstract
The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) is the most variable antigenic fragment in the whole viral genome and is mainly responsible for the large inter- and intra-individual heterogeneity of the infecting virus. It contains a principal neutralization epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, developing an effective prevention therapy is a very difficult task. We have approached the problem of HVR1 variability by deriving a consensus profile from >200 HVR1 sequences from different viral isolates and used it as a template to generate a vast repertoire of synthetic HVR1 surrogates displayed on M13 bacteriophage. This library was affinity selected using many different sera from infected patients. Phages were identified which react very frequently with patients' sera and bind serum antibodies that cross-react with a large panel of HVR1 peptides derived from natural HCV variants. When injected into experimental animals, the ‘mimotopes’ with the highest cross-reactivity induced antibodies which recognized the same panel of natural HVR1 variants. In these mimotopes we identified a sequence pattern responsible for the observed cross-reactivity. These data may hold the key for future development of a prophylactic vaccine against HCV. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
30. 195 Hepatitis C Virus-Specific Immune Response Among Egyptian Healthcare Workers at High Risk of Infection Without Viremia or Seroconversion∗.
- Author
-
Abdelwahab, S, Rewisha, Eman, Sobhy, Maha, Galal, Iman, Zakaria, Zainab A, Mahmoud, Mohamed A, Capone, Stefania, Folgori, Antonella, Hashem, Mohamed, El-Kamary, Samer S, Strickland, G Thomas, Cortese, Riccardo, and Nicosia, Alfredo
- Published
- 2011
- Full Text
- View/download PDF
31. Viral Entry Inhibitors Targeted to the Membrane Site of Action.
- Author
-
Porotto, Matteo, Yokoyama, Christine C., Palermo, Laura M., Mungall, Bruce, Aljofan, Mohamad, Cortese, Riccardo, Pessi, Antonello, and Moscona, Anne
- Subjects
- *
INFECTION , *PROTEIN conformation , *PEPTIDES , *DNA-binding proteins , *PARAINFLUENZA viruses - Abstract
The fusion of enveloped viruses with the host cell is driven by specialized fusion proteins to initiate infection. The "class I" fusion proteins harbor two regions, typically two heptad repeat (HR) domains, which are central to the complex conformational changes leading to fusion: the first heptad repeat (HRN) is adjacent to the fusion peptide, while the second (HRC) immediately precedes the transmembrane domain. Peptides derived from the HR regions can inhibit fusion, and one HR peptide, T20 (enfuvirtide), is in clinical use for HIV-1. For paramyxoviruses, the activities of two membrane proteins, the receptor-binding protein (hemagglutinin-neuraminidase [HN] or G) and the fusion protein (F), initiate viral entry. The binding of HN or G to its receptor on a target cell triggers the activation of F, which then inserts into the target cell and mediates the membrane fusion that initiates infection. We have shown that for paramyxoviruses, the inhibitory efficacy of HR peptides is inversely proportional to the rate of F activation. For HIV-1, the antiviral potency of an HRC-derived peptide can be dramatically increased by targeting it to the membrane microdomains where fusion occurs, via the addition of a cholesterol group. We report here that for three paramyxoviruses--human parainfluenza virus type 3 (HPIV3), a major cause of lower respiratory tract diseases in infants, and the emerging zoonotic viruses Hendra virus (HeV) and Nipah virus (NiV), which cause lethal central nervous system diseases--the addition of cholesterol to a paramyxovirus HRC-derived peptide increased antiviral potency by 2 log units. Our data suggest that this enhanced activity is indeed the result of the targeting of the peptide to the plasma membrane, where fusion occurs. The cholesterol-tagged peptides on the cell surface create a protective antiviral shield, target the F protein directly at its site of action, and expand the potential utility of inhibitory peptides for paramyxoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants.
- Author
-
Catanese, Maria Teresa, Ansuini, Helenia, Graziani, Rita, Huby, Thierry, Moreau, Martine, Ball, Jonathan K., Paonessa, Giacomo, Rice, Charles M., Cortese, Riccardo, Vitelli, Alessandra, and Nicosia, Alfredo
- Subjects
- *
HEPATITIS C virus , *CELL membranes , *LIPOPROTEINS , *VIRION , *CELL culture , *MONOCLONAL antibodies , *LABORATORY mice - Abstract
Scavenger receptor class B type I (SR-BI) is an essential receptor for hepatitis C virus (HCV) and a cell surface high-density-lipoprotein (HDL) receptor. The mechanism of SR-BI-mediated HCV entry, however, is not clearly understood, and the specific protein determinants required for the recognition of the virus envelope are not known. HCV infection is strictly linked to lipoprotein metabolism, and HCV virions may initially interact with SR-BI through associated lipoproteins before subsequent direct interactions of the viral glycoproteins with SR-BI occur. The kinetics of inhibition of cell culture-derived HCV (HCVcc) infection with an anti-SR-BI monoclonal antibody imply that the recognition of SR-BI by HCV is an early event of the infection process. Swapping and single-substitution mutants between mouse and human SR-BI sequences showed reduced binding to the recombinant soluble E2 (sE2) envelope glycoprotein, thus suggesting that the SR-BI interaction with the HCV envelope is likely to involve species-specific protein elements. Most importantly, SR-BI mutants defective for sE2 binding, although retaining wild-type activity for receptor oligomerization and binding to the physiological ligand HDL, were impaired in their ability to fully restore HCVcc infectivity when transduced into an SR-BI-knocked-down Huh-7.5 cell line. These findings suggest a specific and direct role for the identified residues in binding HCV and mediating virus entry. Moreover, the observation that different regions of SR-BI are involved in HCV and HDL binding supports the hypothesis that new therapeutic strategies aimed at interfering with virus/SR-BI recognition are feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein.
- Author
-
Catanese, Maria Teresa, Graziani, Rita, Von Hahn, Thomas, Moreau, Martine, Huby, Thierry, Paonessa, Giacomo, Santini, Claudia, Luzzago, Alessandra, Rice, Charles M., Cortese, Riccardo, Vitelli, Alessandra, and Nicosia, Alfredo
- Subjects
- *
MONOCLONAL antibodies , *HEPATITIS C virus , *VIRUS diseases , *LIPOPROTEINS , *GLYCOPROTEINS , *CELL culture - Abstract
The human scavenger class B type 1 receptor (SR-B1/Cla1) was identified as a putative receptor for hepatitis C virus (HCV) because it binds to soluble recombinant HCV envelope glycoprotein E2 (sE2). High-density lipoprotein (HDL), a natural SR-B1 ligand, was shown to increase the in vitro infectivity of retroviral pseudoparticles bearing HCV envelope glycoproteins and of cell culture-derived HCV (HCVcc), suggesting that SR-B1 promotes viral entry in an HDL-dependent manner. To determine whether SR-B1 participates directly in HCV infection or facilitates HCV entry through lipoprotein uptake, we generated a panel of monoclonal antibodies (MAbs) against native human SR-B1. Two of them, 3D5 and C167, bound to conformation-dependent SR-B1 determinants and inhibited the interaction of sE2 with SR-B1. These antibodies efficiently blocked HCVcc infection of Huh-7.5 hepatoma cells in a dose-dependent manner. To examine the role of HDL in SR-B1-mediated HCVcc infection, we set up conditions for HCVcc production and infection in serum-free medium. HCVcc efficiently infected Huh-7.5 cells in the absence of serum lipoproteins, and addition of HDL led to a twofold increase in infectivity. However, the HDL-induced enhancement of infection had no impact on the neutralization potency of MAb C167, despite its ability to inhibit both HDL binding to cells and SR-B1-mediated lipid transfer. Of note, MAb C167 also potently blocked Huh-7.5 infection by an HCV strain recovered from HCVcc-infected chimpanzees. These results demonstrate that SR-B1 is essential for infection with HCV produced in vitro and in vivo and suggest the possible use of anti-SR-B1 antibodies as therapeutic agents. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.